Oxford, UK, October 20th, 2011 – PharmaVentures today announced the launch of PharmaDeals® Essential Deal Trends: Oncology 2011. This new series of reports is essential reading for everyone involved in developing and commercialising new drugs. The first report in the series focuses on oncology.

Oncology is the single most active deal making therapeutic area in the pharmaceutical and biotechnology industry. With such a high intensity of deal making, executives across the industry need the best information and insight to support their business decisions in this vital drive to make better drugs available for patients. PharmaDeals Essential Deal Trends: Oncology 2011 provides the data and insight that dealmakers need to be as effective as possible. Featuring all the key providers of therapies in the oncology field, including Pfizer, Genentech, Sanofi, Merck, GSK and others, the Essential Deal Trends series provides the most comprehensive deal trends coverage available. Other key deal intensive therapeutic areas including cardiovascular, CNS and respiratory will be published in the following months. Available in the iReport format with over 100 tables and figures in each report, you can extract data and tables for your own analysis and presentations.

Fintan Walton, Chief Executive of PharmaVentures, says, “Deal makers from large pharmaceutical companies to small biotechs tell us they need a high quality publication that helps them best understand the key players and deal trends in this and other vital areas of medicine. We are proud to be able to use our extensive data resources and analytical insight to produce this first in a series of key reports for the industry.”

For further information, contact:

Lisa Holloway 

Senior Direct Marketing Manager

+44 1865 332700

lisa.holloway@pharmaventures.com

– ends –

Oxford, UK 26 September 2011 – PharmaVentures, the experts in deals and alliances, announced today that Corp-METRx, the new definitive analysis on the dealmaking and financial performance of the top 12 pharmaceutical companies, is launched.

The first release of this monthly report on all of the top 12 pharmaceutical companies shows Pfizer has overtaken GlaxoSmithKline and are now placed second only to Roche in the industry’s new Deal Activity League Table*. The first monthly edition is available as a free download on our website (www.pharmadeals.net/corpmetrx). The ranking information and expert insight from PharmaVentures will be invaluable to analysts, M&A and corporate finance professionals in investment banks, hedge funds, large cap advisory and asset management firms as well as business development and competitive intelligence professionals, chief executives and other senior managers within pharmaceutical and biotechnology companies.

PharmaDeals® Corp-METRx provides key metrics on the relative strengths and weaknesses of the world’s top 12 pharmaceutical companies, and is delivered in a concise and instantly accessible online format. This new publication, edited by PharmaVentures’ expert, Nigel Borshell, provides an essential look-up for key facts about how major pharmaceutical companies’ deal making activities vary, the impact this has on their peer group ranking and how this evolves with time.

Anne Vindenes Allen, PharmaDeals’ Executive Director, says, “The industry was in need of a report that would readily analyse how well top companies are performing as deal makers, andPharmaDeals Corp-METRx does just that. Reports on each company are available, along with our expert assessment reviewing the changes of all those 12 companies.”

Download the free first edition of PharmaDeals Corp-METRx and read the monthly review article now:

www.pharmadeals.net/corpmetrx

For further information, contact:

Anne Vindenes Allen

Executive Director, PharmaDeals

+44 1865 332700

anne.allen@pharmaventures.com

– ends –

Oxford, UK 09 September 2011 – PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures’ asset divestment expertise in the life sciences sector.

Dr Fintan Walton, CEO, PharmaVentures commented, “We are delighted to have been chosen by Astex to assist in divesting this state-of-the-art facility, maximising return for the stakeholders. With 20 years’ experience of transactions, PharmaVentures can provide Astex with access to key decision makers in relevant companies with a view to safeguarding the future of the site.”

The facility is part of the recent integration of Astex Therapeutics Limited and SuperGen Inc. and provides an opportunity to build out a fully integrated CMC capability in a prime but low cost West Coast US location. The site’s team has significant experience in preclinical as well as Phase I, II and III drug product development as evidenced by over 30 patents and the successful oversight of a number of global regulatory filings.

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. The transactions team has an established track record in generating outstanding value for PharmaVentures’ clients and has assisted in over 100 transactions in the past 20 years.

For enquiries regarding this opportunity or how we can help your company to achieve its business goals, please contact:

Dr Jansen Jacob

Senior Advisor

PharmaVentures Ltd

+44 7951 205420

– ends –

Oxford, UK 12 July 2011 – PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by Avexa Limited to seek an out-licensing partner for apricitabine (ATC), a late-stage, novel treatment for HIV infection. The engagement will utilise PharmaVentures’ global transactional expertise in the healthcare and investment business sectors.

Dr Fintan Walton, CEO, PharmaVentures commented, “We are delighted to have been chosen by Avexa to assist in achieving its business goal of maximising the return on investment in its development compound apricitabine (ATC). With 20 years’ experience of deals and alliances, PharmaVentures can provide Avexa with immediate access to extensive licensing expertise and a network of key decision makers in relevant companies”

Iain Kirkwood, Chairman of Avexa said, “the appointment of PharmaVentures to work with and complement our management team is the next logical step in the commercialisation of ATC following our successful regulatory meeting with the FDA earlier this year. PharmaVentures have an excellent reputation and track record in this area.”

ATC is a novel nucleoside, a class of compound known to be a vital component of anti-HIV therapy. ATC offers a new extension to existing therapies in the treatment of drug-resistant HIV, especially for those patients with limited remaining therapeutic options.

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. The licensing team has an established track record in generating outstanding value for PharmaVentures’ clients and has assisted in over 100 transactions in the past 20 years.

For enquiries regarding this licensing opportunity or how we can help your company to achieve its business goals, please contact:

Kevin Bottomley

Head of Transactions

PharmaVentures Ltd.

+44 7931 144097

– ends –

Oxford UK, 28 June 2011: PharmaVentures, experts in deals and alliances, are pleased to announce that they have recently been engaged by two major pharmaceutical companies to divest three facilities in three continents:

These new M&A mandates follow fast on the imminent closure of a sale of a European R&D facility and the successful divestment of three facilities for UCB and two for sanofi.

Fintan Walton, CEO of PharmaVentures, commented ” At PharmaVentures we are seeing an increasing number of top tier pharmaceutical companies looking to divest facilities as a result of consolidation or restructuring within their businesses. They trust PharmaVentures to provide the specialist skills and experience in valuing and positioning their assets for sale and then conducting a thorough proven process to deliver the best outcome. We are delighted that so many of the top Pharmaceutical companies recognise us as the provider of choice for these services.”

Kevin Bottomley, Head of Transactions stated ” Many of these facilities are very specialist and require expert knowledge to understand and convey the true value to potential acquirers. In selling these sites for continued or new uses we have been able to secure the future employment of thousands of people and facilitate new business growth.”

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. The transaction team has an established track record in generating outstanding value for PharmaVentures’ clients and has assisted in over 100 transactions in the past 20 years. Beyond that, PharmaVentures’ senior advisors have assisted over 500 leading companies in their growth needs including the areas of partnering and M&A.

– ends –